Oppenheimer Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $163
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has maintained an Outperform rating on Praxis Precision Medicine (NASDAQ:PRAX) and raised the price target from $143 to $163.
October 31, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained an Outperform rating on Praxis Precision Medicine and increased the price target from $143 to $163, indicating positive expectations for the stock.
The increase in price target from $143 to $163 by Oppenheimer suggests a positive outlook for Praxis Precision Medicine, likely leading to a short-term increase in stock price. The Outperform rating further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100